Document is current
Any future updates will be listed below
-
Authors
Nishida, Kazuki
Chrétien, Basile
Muraoka, Shinsuke https://orcid.org/0000-0003-4225-110X
Izumi, Takashi
Nishihori, Masahiro
Goto, Shunsaku
Takeuchi, Issei
Tashiro, Ryosuke
Sakata, Hiroyuki
Vivien, Denis
Mizuno, Masaaki
Endo, Hidenori
Saito, Ryuta
-
Funding
Funding for this research was provided by:
Nagoya University Hospital Funding for Clinical Research
Japan Research Foundation for Clinical Pharmacology
NXERA Phama
Nagoya University
- License Information
-
More Information
Article History
Received: 29 January 2026
Accepted: 29 May 2026
First Online: 17 June 2026
Conflict of interest
: Ryuta Saito reports an endowed chair funded by Nxera Pharma; the company had no role in data collection, analysis, or manuscript preparation. Hidenori Endo reports a donated research division (2024–2026) from Nxera Pharma titled “Development of Diagnosis and Treatment for Subarachnoid Hemorrhage.” All other authors declare no conflict of interest related to clazosentan.
: This study is an analysis based on the RECOVER study. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Nagoya University Hospital (approval number: 2022–0476). Informed consent for this secondary analysis was waived because the analysis was performed using anonymized clinical data. Patient notification/approval was provided through an IRB-approved opt-out procedure (opt-out poster displayed in the outpatient department and the neurosurgery ward).
: ChatGPT (OpenAI, San Francisco, CA) was used to rewrite and summarize portions of the manuscript for clarity and readability.
